Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cidara Therapeutics Inc    CDTX

CIDARA THERAPEUTICS INC (CDTX)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/17/2017 10/18/2017 10/19/2017 10/20/2017 10/23/2017 Date
6.7(c) 6.35(c) 6.9(c) 7.5(c) 7.675 Last
69 083 94 512 118 544 125 604 94 208 Volume
-2.90% -5.22% +8.66% +8.70% +2.33% Change
More quotes
Financials ($)
Sales 2017 0,38 M
EBIT 2017 -62,2 M
Net income 2017 -62,4 M
Finance 2017 36,2 M
Yield 2017 -
Sales 2018 0,88 M
EBIT 2018 -69,1 M
Net income 2018 -69,5 M
Finance 2018 60,8 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 241x
EV / Sales2018 74,4x
Capitalization 126 M
More Financials
Company
Cidara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of anti-infectives for the treatment of fungal infections.Its portfolio includes CD101 IV, CD101 Topical, and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J.... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Cidara Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CIDARA THERAPEUTICS INC
10/20 CIDARA THERAPEUTICS : Announces Pricing of $20 Million Private Placement of Comm..
10/20 CIDARA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Financia..
10/19 Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Com..
09/25 Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends..
09/18 Cidara Therapeutics to Present at Two Upcoming Conferences
09/07 Cidara Therapeutics to Participate in Keynote Panel Discussion at the 2017 Wo..
09/07 T2 BIOSYSTEMS : and Cidara Therapeutics Announce Partnership for Commercial Plac..
08/10 CIDARA THERAPEUTICS : Announces Publication of Results from In Vivo Study Invest..
08/10 CIDARA THERAPEUTICS : reports 2Q loss
08/09 Cidara Provides Corporate Update and Reports Second Quarter 2017 Financial Re..
More news
Sector news : Bio Therapeutic Drugs
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Bio Therapeutic Drugs
Latest Tweets
10/22
1
10/19Cidara Therapeutics $CDTX Getting Somewhat Favorable Press Coverage, Study Sh.. 
10/19  
10/19$CDTX: Cidara Therapeutics prices private placement of 3,360,000 shares of it..
1
10/19Cidara Therapeutics Announces Pricing of $20 Million Private Placement of Com.. 
More tweets
Qtime:45
News from SeekingAlpha
10/22 WEEK 43 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge
10/19 CIDARA THERAPEUTICS : Buy The Secondary
10/19 Cidara prices private placement of shares at $6; shares up 2%
09/27 Cidara Therapeutics (CDTX) Presents At Ladenburg Thalmann 2017 Healthcare Con..
09/26 Cidara Therapeutics (CDTX) Presents At Cantor Fitzgerald Global Healthcare Co..
Chart CIDARA THERAPEUTICS INC
Duration : Period :
Cidara Therapeutics Inc Technical Analysis Chart | CDTX | US1717571079 | 4-Traders
Technical analysis trends CIDARA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 13,3 $
Spread / Average Target 77%
EPS Revisions
Managers
NameTitle
Jeffrey L. Stein President, Chief Executive Officer & Director
Scott M. Rocklage Chairman
Matthew W. Onaitis CFO, Secretary & General Counsel
Taylor Sandison Chief Medical Officer
Theodore R. Schroeder Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CIDARA THERAPEUTICS INC-27.88%126
GILEAD SCIENCES13.41%106 054
REGENERON PHARMACEUTICALS17.95%46 395
VERTEX PHARMACEUTICALS109.90%38 985
ACTELION24.15%29 840
GENMAB13.21%12 865